MTSL Issue 825

 Comments Off on MTSL Issue 825
Apr 172016
 
MTSL Issue 825

MTSL Issue 825 (dated 4/14/16) of the Medical Technology #Stock Letter from BioInvest includes the #Biotech Sector Analysis as well as updates from the following companies: #BMRN #IONS #XON #MDCO

MTSL Issue 816

 Comments Off on MTSL Issue 816
Dec 062015
 
MTSL Issue 816

Issue No. 816 (dated 12/3/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #BMRN #XON #MDCO #NKTR #NVAX #OGXI #SGMO #ZIOP

BioMarin Update (2-22-13)

 Comments Off on BioMarin Update (2-22-13)
Feb 222013
 
BioMarin Update (2-22-13)

The Orphan Drugs Leader. With 2012 exceeding $500 million, BioMarin has vaulted itself into an elite group of the top-tier biotech companies.  Naglazyme ($257 million, +14% Y/Y) and Kuvan ($143 million, +23%) each had solid years and royalties from Aldurazyme ($80 million, +6%) continue to deliver strong cash flow. With a truly impressive pipeline filled […]

BioMarin Update (11-16-12)

 Comments Off on BioMarin Update (11-16-12)
Nov 162012
 
BioMarin Update (11-16-12)

BioMarin’s stock is up significantly since the last Issue. The trigger for the strong price move was positive data from their Phase III trial in patients with the rare genetic disorder known as Morquio A Syndrome. The patients treated with a weekly infusion of GALNS were able to walk an average of 22.5 meters further […]